"Protalix, a biopharmaceutical company specializing in the development of innovative therapies, closed at $10.71 on Friday on the American Stock Exchange, showcasing a slight increase and reflecting positive investor sentiment. This resulted in a market cap of $827 million, indicating continued confidence in the company's future prospects amidst the current market conditions."